For instance, the small molecule CSF1R inhibitor BLZ945 blocked the progression of glioma in preclinical models (13), and the anti-CSF1R antibody RG7155 reduced tumor burden in patients with diffuse-type giant cell tumors (14). This evidence concerns the gene CSF1R and central nervous system cancer.